Press Release

Dr. William Chin to Lead Science & Regulatory Affairs

PhRMA June 3, 2013

WASHINGTON, D.C. (June 3, 2013) –  The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Dr. William Chin will become Executive Vice President of Science and Regulatory Affairs, effective July 1, 2013. Dr. Chin will report to PhRMA President and CEO John J. Castellani and serve as a member of the PhRMA Management Committee.

Dr. Chin is currently the Executive Dean for Research at Harvard Medical School. At PhRMA, he will oversee the organization’s scientific and regulatory affairs portfolio, including implementation of the Prescription Drug User Fee Act (PDUFA), clinical trials, and drug discovery and research collaboration, among other key issues.

“As the biopharmaceutical sector faces exciting and evolving scientific opportunities, we must have a strong and respected voice in the discovery ecosystem and ensure the scientific and regulatory processes advance rapidly to meet patient needs,” said Castellani. “We are very pleased that Bill Chin is joining PhRMA at this important juncture and look forward to working with him to support the development of innovative medicines and ultimately helping patients live longer, healthier lives.”

“I am thrilled to take on this leadership role for PhRMA at a time when medical science and transformative biomedical advances promise new therapies for men, women and children,” said Dr. Chin. "My vision includes establishing PhRMA as the premiere convener of those individuals who can serve as a catalyst for advancing drug discovery and development, regulatory sciences and collaborative partnerships.”

Dr. Chin is an internist and endocrinologist who spent much of his early career studying the molecular mechanisms of hormonal control of gene expression.  After 25 years in academia with activities in research, teaching, patient care and administration, including stints as a Howard Hughes Medical Institute Investigator, Professor of Medicine at Harvard Medical School (HMS) and Chief, Division of Genetics at the Brigham & Women’s Hospital, Dr. Chin joined Eli Lilly & Company in 1999. 

During his 11 years at Eli Lilly, Dr. Chin first served as vice president of discovery biology research and clinical investigation and beginning in 2006, managed the company’s global drug discovery and clinical investigation efforts. He led a large group of biologists, chemists, toxicologists, ADME and regulatory experts, pharmacologists, and experimental medicine scientists who fostered the creation of more than 130 clinical candidates, many of which continue to undergo later-stage clinical trials. 

In 2010, Dr. Chin returned to Harvard Medical School as the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine.  His responsibilities included fostering interdisciplinary and interdepartmental research, developing new approaches to academic-industry interactions, and initiating a new program in therapeutics, including regulatory sciences.

Dr. Chin has served on numerous boards and advisory committees, such as the Scientific Advisory Board for A*STAR and the Biomedical Research Council in Singapore, the Board of the Reagan Udall Foundation and the Scientific Advisory Board of the Juvenile Diabetes Research Foundation.  Dr. Chin received his A.B. in chemistry from Columbia College and his medical degree from Harvard Medical School.


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested approximately $550 billion in the search for new treatments and cures, including an estimated $48.5 billion in 2012 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on ensuring the flow of medicines during public health emergencies, visit